Adipose Cellular Kinetics of Lipedema

Lipedema Clinical Trial

— LIPEDEMA  

Official title:

A Novel Approach to Examine the Adipose Cellular Kinetics of Lipedema

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05394467
• Other study ID #: PBRC 2021-051
• Status: Recruiting
• Start date: April 7, 2022
• Est. completion date: February 28, 2025

Study information

• Verified date: June 2024
• Source: Pennington Biomedical Research Center
• Contact: Ursula White, PhD
• Phone: 2257632656
• Email: ursula.white[@]pbrc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lipedema is characterized by an abnormal deposition of adipose tissue, resulting in fluid accumulation, limb enlargement, and pain. Lipedema is often misdiagnosed as simply obesity. A major challenge with diagnosis is the poorly understood biology underlying the disease. Limited studies suggest that the development of lipedema may involve adipocyte hypertrophy, increased commitment of adipose progenitor cells, hypoxia, adipocyte necrosis and macrophage recruitment. There remains an urgent need to investigate novel characteristics of adipose remodeling that may contribute to the pathogenesis of lipedema. The study investigators have reported quantitative measures of in vivo adipose kinetics using an 8-week incorporation of deuterium (administered as 2H2O) into the adipose tissue of women with obesity. The objective of this proposal is to utilize the metabolic 2H-labeling approach to measure, for the first time, in vivo adipocyte formation and triglyceride synthesis in the adipose tissue of participants with lipedema. Imaging approaches will provide a range of measurements to characterize the lipedema depots. The investigators hypothesize that lipedema adipose depots will have higher rates of adipocyte formation and triglyceride synthesis than both non-lipedema depots and those of women with traditional obesity. Lipedema may involve adipose tissue remodeling, characterized by adipocyte hypertrophy and increased commitment of preadipocytes and differentiation of adipocytes (adipogenesis), yielding an abundance of adipocytes with limited capacity to expand and accommodate lipid, resulting in hypoxia, macrophage recruitment, and local/systemic inflammation. Findings from this proposal will contribute to a better understanding of the pathogenesis of lipedema and may provide insight for the future development of therapeutic targets.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: February 28, 2025
• Est. primary completion date: February 28, 2025
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• BMI =50 kg/m2

• Waist/hip ratio <0.86 (standing position)

• Clinical diagnosis of lipedema (mostly Stage 3 but Stage 2 will not be excluded)

• Willing to drink deuterated water (2H2O)

Exclusion Criteria:

• Have major organ disease (heart, kidney, lung, thyroid, liver) or abnormal liver enzymes that represent a problem for study inclusion

• Chronic use of systemic glucocorticoids, atypical anti-psychotic medications, or medications that cause clinically significant changes in weight

• Pregnancy or breastfeeding in the next 3 months

• Partial and/or full hysterectomy (due to estrogen effects on adipogenesis)

• PCOS

• Self-reported positive test for HIV, hepatitis B and hepatitis C

• Smoking or use of tobacco products in the last 6 months

• Any medical, psychiatric or behavioral factors that may interfere with study participation

Related Conditions & MeSH terms

• Lipedema

Locations

Country	Name	City	State
United States	Pennington Biomedical Research Center	Baton Rouge	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Pennington Biomedical Research Center	Lipedema Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess in vivo adipocyte formation in lipedema adipose depots (femoral) and non-lipedema depots (abdominal,) from patients with lipedema.	Following the consumption of deuterium-labeled water (2H2O; heavy water), adipose tissue biopsies from the subcutaneous abdominal and femoral depots will be collected. The 2H from the heavy water is enriched into the DNA of newly formed adipocytes. Lipedema adipose depots (femoral) will be compared to non-lipedema depots (abdominal) in these women with lipedema.	8 weeks
Secondary	Assess in vivo triglyceride formation in lipedema adipose depots (femoral) and non-lipedema depots (abdominal,) from patients with lipedema.	Following the consumption of deuterium-labeled water (2H2O; heavy water), adipose tissue biopsies from the subcutaneous abdominal and femoral depots will be collected. The 2H from the heavy water is enriched into the glycerol moiety of triglycerides, reflecting recent triglyceride formation. Lipedema adipose depots (femoral) will be compared to non-lipedema depots (abdominal) in these women with lipedema.	8 weeks